OBJECTIVE: Prominent fibrinogen cleavage by recombinant tissue plasminogen activator and formation of fibrinogen degradation products with anticoagulant properties was proposed to amplify the risk of thrombolysis-related bleeding complications, but supportive evidence mainly derived from studies on myocardial infarction. METHODS: This study included 547 consecutive stroke patients treated with recombinant tissue plasminogen activator, who underwent repeated assessment of fibrinogen levels before and 6 hours after thrombolysis. Symptomatic intracranial hemorrhages were ascertained using National Institute of Neurological Disorders and Stroke criteria. RESULTS: Intracranial hemorrhage or systemic bleeding events manifested in 47 patients (8.6%). A decrease ≥200 mg/dL in the fibrinogen level 6 hours after thrombolysis emerged as a significant and independent predictor for bleeding risk (multivariable odds ratio [95% confidence interval] 4.53 [2.39-8.60], p < 0.001). The population-attributable risk was 39.9% (95% confidence interval, 19.0-60.2) for any major bleeding, causality assumed, and surpassed 50% in patients with less severe strokes (NIH Stroke Scale score ≤16). Quantification of fibrinogen depletion after stroke thrombolysis significantly improved routine risk prediction of bleeding complications as indicated by an increase in the C-statistics from 0.712 to 0.798 (p = 0.015) and a net reclassification index of 0.341 (p < 0.001). A prospective bicenter validation sample (n = 148) corroborates the key findings of this study and suggests positive and negative predictive values of fibrinogen depletion for any major bleeding of 29.2% and 93.5%. CONCLUSION: This study lends strong support to the concept that prominent fibrinogen turnover after IV stroke thrombolysis-a condition termed "early fibrinogen degradation coagulopathy"-is a relevant cause of major bleeding complications. Rigorous testing of more fibrin-specific thrombolytic agents in the setting of acute stroke is warranted.
OBJECTIVE: Prominent fibrinogen cleavage by recombinant tissue plasminogen activator and formation of fibrinogen degradation products with anticoagulant properties was proposed to amplify the risk of thrombolysis-related bleeding complications, but supportive evidence mainly derived from studies on myocardial infarction. METHODS: This study included 547 consecutive strokepatients treated with recombinant tissue plasminogen activator, who underwent repeated assessment of fibrinogen levels before and 6 hours after thrombolysis. Symptomatic intracranial hemorrhages were ascertained using National Institute of Neurological Disorders and Stroke criteria. RESULTS:Intracranial hemorrhage or systemic bleeding events manifested in 47 patients (8.6%). A decrease ≥200 mg/dL in the fibrinogen level 6 hours after thrombolysis emerged as a significant and independent predictor for bleeding risk (multivariable odds ratio [95% confidence interval] 4.53 [2.39-8.60], p < 0.001). The population-attributable risk was 39.9% (95% confidence interval, 19.0-60.2) for any major bleeding, causality assumed, and surpassed 50% in patients with less severe strokes (NIH Stroke Scale score ≤16). Quantification of fibrinogen depletion after stroke thrombolysis significantly improved routine risk prediction of bleeding complications as indicated by an increase in the C-statistics from 0.712 to 0.798 (p = 0.015) and a net reclassification index of 0.341 (p < 0.001). A prospective bicenter validation sample (n = 148) corroborates the key findings of this study and suggests positive and negative predictive values of fibrinogen depletion for any major bleeding of 29.2% and 93.5%. CONCLUSION: This study lends strong support to the concept that prominent fibrinogen turnover after IV stroke thrombolysis-a condition termed "early fibrinogen degradation coagulopathy"-is a relevant cause of major bleeding complications. Rigorous testing of more fibrin-specific thrombolytic agents in the setting of acute stroke is warranted.
Authors: Joshua A Stone; Joshua Z Willey; Salah Keyrouz; James Butera; Ryan A McTaggart; Shawna Cutting; Brian Silver; Bradford Thompson; Karen L Furie; Shadi Yaghi Journal: Curr Treat Options Neurol Date: 2017-01 Impact factor: 3.598
Authors: Matthew P Lillyblad; Ghaziuddin A Qadri; Brynn E Weise; Claire S Smith; Catherine St Hill; David M Tierney; Roman R Melamed Journal: J Thromb Thrombolysis Date: 2022-03-23 Impact factor: 2.300
Authors: Luis Prats-Sanchez; Alejandro Martínez-Domeño; Pol Camps-Renom; Raquel Delgado-Mederos; Daniel Guisado-Alonso; Rebeca Marín; Laura Dorado; Salvatore Rudilosso; Alejandra Gómez-González; Francisco Purroy; Manuel Gómez-Choco; David Cánovas; Dolores Cocho; Moises Garces; Sonia Abilleira; Joan Martí-Fàbregas Journal: PLoS One Date: 2017-06-22 Impact factor: 3.240
Authors: Megan E Barra; Steven K Feske; Katelyn W Sylvester; Charlene Ong; Sarah E Culbreth; Patricia Krause; Galen V Henderson; Eva Rybak Journal: Clin Appl Thromb Hemost Date: 2020 Jan-Dec Impact factor: 2.389
Authors: Slaven Pikija; Vladimir Trkulja; Johannes Sebastian Mutzenbach; Mark R McCoy; Patricia Ganger; Johann Sellner Journal: J Transl Med Date: 2016-08-30 Impact factor: 5.531